All In Biotech

Free tool

FAERS Monitor: Lysodren

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 016885 or its brand name (Lysodren, Mitotane). Reports on generic versions are filed under their own applications.

Reports

1,830

Serious

1,299

71% of reports

Hospitalization

499

Death reported

237

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea319
  • off label use307
  • fatigue291
  • diarrhoea173
  • vomiting157
  • product dose omission issue142
  • adrenal insufficiency134
  • drug ineffective132
  • dizziness120
  • decreased appetite117
  • asthenia105
  • death88
  • malignant neoplasm progression82
  • disease progression78
  • drug interaction74

Reports by year received

View as table
YearReports
200412
20057
20068
200727
200826
200930
201018
201139
201258
201338
201421
201543
201641
201759
2018122
201955
202082
2021114
2022171
2023180
2024228
2025193
2026257

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
adrenal insufficiencySignal134128.3108.916,625
malignant neoplasm progressionSignal829.27.5594
disease progressionSignal787.66.1441
decreased appetiteSignal1175.84.9464
product dose omission issueSignal1425.64.7533
drug interactionSignal745.44.3260
nauseaSignal3194.64.2940
fatigueSignal2914.33.9761
off label useSignal3074.03.6727
vomitingSignal1573.83.3334
astheniaSignal1053.22.7160
diarrhoeaSignal1733.12.7249
dizzinessSignal1202.82.3137
death881.21.02
drug ineffective1321.21.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.